Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5), commonly known as GLUT5, is a member of the major facilitator superfamily that functions as a highly specific facilitative fructose transporter. It is primarily expressed in the apical membrane of enterocytes in the small intestine, where it mediates dietary fructose absorption, as well as in the kidneys, skeletal muscle, and microglia. While physiologically essential for fructose uptake and metabolic homeostasis, SLC2A5 is frequently upregulated in various malignancies, including breast, colorectal, and lung cancers, where it supports tumor cell proliferation, migration, and metastasis by fueling the fructose-tumor feeding axis.
Consequently, SLC2A5 has emerged as an attractive therapeutic target in oncology and metabolic diseases like non-alcoholic fatty liver disease (NAFLD) and obesity. Pharmacological targeting of SLC2A5 involves small-molecule inhibitors such as MSNBA and the clinical candidate S-700, which aim to block fructose uptake and disrupt cancer cell metabolism or alleviate metabolic syndrome. However, therapeutic challenges include avoiding off-target inhibition of other glucose transporters (like GLUT1 or GLUT4) and managing potential gastrointestinal side effects resembling fructose malabsorption.
Inhibition of facilitative fructose transport across the cell membrane, either through competitive binding at the active site, allosteric modulation, or transcriptional downregulation of transporter expression.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5).